Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca.

Innate Pharma SA announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca. Innate licensed the US and EU rights to AstraZeneca’s FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in October 2018. The companies will develop a transition plan, including costs and transfer of the US marketing authorization and distribution of Lumoxiti back to AstraZeneca in 2021. AstraZeneca will remain the marketing authorization applicant for the EU filing. Lumoxiti was approved by the FDA in September 2018 and EMA has accepted a MAA in January 2020.